Results 41 to 50 of about 12,875 (250)

ADAMTS13 Biomarkers in Management of Immune Thrombotic Thrombocytopenic Purpura.

Archives of Pathology & Laboratory Medicine, 2022
CONTEXT.— Immune thrombotic thrombocytopenic purpura (iTTP) is a rare but potentially fatal blood disorder resulting from acquired deficiency of plasma ADAMTS13, a metalloprotease that cleaves endothelium-derived ultralarge von Willebrand factor ...
Jingrui Sui, Liang Zheng, X. Zheng
semanticscholar   +1 more source

AFM Imaging Reveals Multiple Conformational States of ADAMTS13

Journal of Biological Engineering, 2019
Background ADAMTS13 (A disintegrin and metalloprotease with a thrombospondin type 1 motif 13) cleaves Von Willebrand factor (VWF) to regulate its size, thereby preventing aberrant platelet aggregation and thrombus. Deficiency of ADAMTS13 caused by either
Shanshan Yu, Wang Liu, Jinhua Fang, Xiaozhong Shi, Jianhua Wu, Ying Fang, Jiangguo Lin   +6 more
doaj   +1 more source

Contribution of ADAMTS13‐independent VWF regulation in sickle cell disease

Journal of Thrombosis and Haemostasis, 2022
Von Willebrand factor (VWF) is elevated in sickle cell disease (SCD) and contributes to vaso‐occlusion through its thrombogenic properties. VWF is regulated by ADAMTS13, a plasma protease that cleaves VWF into less bioactive multimers.
R. Hunt, Upendra K. Katneni, Ayla Yalamanoglu, F. Indig, J. Ibla, C. Kimchi-Sarfaty   +5 more
semanticscholar   +1 more source

Bethesda Assay for Detecting Inhibitory Anti-ADAMTS13 Antibodies in Immune-Mediated Thrombotic Thrombocytopenic Purpura

TH Open, 2018
A diagnosis of thrombotic thrombocytopenic purpura (TTP) is confirmed by a severe deficiency (
Chiara Vendramin, Mari Thomas, John-Paul Westwood, Marie Scully   +3 more
doaj   +1 more source

Upshaw-Schulman syndrome-associated ADAMTS13 variants possess proteolytic activity at the surface of endothelial cells and in simulated circulation

PLoS ONE, 2020
ADAMTS13 regulates the hemostatic activity of von Willebrand factor (VWF). Determined by static assays, proteolytic activity 
Anton Letzer, Katja Lehmann, C. Mess, G. König, T. Obser, S. Peine, S. Schneppenheim, Ulrich Budde, Stefan W Schneider, Reinhard Schneppenheim, M. Brehm   +10 more
semanticscholar   +1 more source

Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID‐19 patients

Journal of Thrombosis and Haemostasis, 2021
Critically ill patients with coronavirus disease 2019 (COVID‐19) are prone to developing macrothrombosis and microthrombosis. COVID‐19 has been reported to be rarely associated with thrombotic microangiopathies.
B. Joly, M. Darmon, C. Dekimpe, Thibault Dupont, G. Dumas, É. Yvin, Nicolas Béranger, K. Vanhoorelbeke, É. Azoulay, A. Veyradier   +9 more
semanticscholar   +1 more source

Association between ADAMTS13 deficiency and cardiovascular events in chronic hemodialysis patients

Scientific Reports, 2021
A mild decrease of ADAMTS13 (a disintegrin and metalloprotease with thrombospodin type 1 motif 13) could attribute to stroke and coronary heart disease in general population.
Shih-Yuan Hung, Tsun-Mei Lin, Hung-Hsiang Liou, Ching-Yang Chen, Wei-Ting Liao, Hsi-Hao Wang, Li-Chun Ho, Ching-Fang Wu, Yi-Che Lee, Min-Yu Chang   +9 more
doaj   +1 more source

Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. [PDF]

PLoS ONE, 2010
Severe ADAMTS13 deficiency occurs in 13% to 75% of thrombotic microangiopathies (TMA). In this context, the early identification of a severe, antibody-mediated, ADAMTS13 deficiency may allow to start targeted therapies such as B-lymphocytes-depleting ...
Paul Coppo, Michael Schwarzinger, Marc Buffet, Alain Wynckel, Karine Clabault, Claire Presne, Pascale Poullin, Sandrine Malot, Philippe Vanhille, Elie Azoulay, Lionel Galicier, Virginie Lemiale, Jean-Paul Mira, Christophe Ridel, Eric Rondeau, Jacques Pourrat, Stéphane Girault, Dominique Bordessoule, Samir Saheb, Michel Ramakers, Mohamed Hamidou, Jean-Paul Vernant, Bertrand Guidet, Martine Wolf, Agnès Veyradier, French Reference Center for Thrombotic Microangiopathies   +25 more
doaj   +1 more source

Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease. [PDF]

PLoS ONE, 2017
Von Willebrand Factor (VWF) plays a major role in thrombosis and hemostasis and its thrombogenicity is controlled by ADAMTS13. Whereas increasing evidence shows a clear association between VWF levels and acute ischemic stroke, little is known about a ...
Frederik Denorme, Peter Kraft, Inge Pareyn, Christiane Drechsler, Hans Deckmyn, Karen Vanhoorelbeke, Christoph Kleinschnitz, Simon F De Meyer   +7 more
doaj   +1 more source

vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease

Thrombosis Journal, 2017
Background The mechanisms behind residual platelet reactivity (RPR) despite aspirin treatment are not established. It has been shown that coronary artery disease (CAD) patients with high on-aspirin RPR have elevated levels of von Willebrand factor (vWF).
Ellen M. K. Warlo, Alf-Åge R. Pettersen, Harald Arnesen, Ingebjørg Seljeflot   +3 more
doaj   +1 more source